305 related articles for article (PubMed ID: 17204717)
21. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
22. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
23. The role of PET in lymphoma.
Jhanwar YS; Straus DJ
J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
[TBL] [Abstract][Full Text] [Related]
24. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
Quon A; Fischbein NJ; McDougall IR; Le QT; Loo BW; Pinto H; Kaplan MJ
J Nucl Med; 2007 Jan; 48 Suppl 1():58S-67S. PubMed ID: 17204721
[TBL] [Abstract][Full Text] [Related]
25. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
27. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
Saif MW; Cornfeld D; Modarresifar H; Ojha B
J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
[TBL] [Abstract][Full Text] [Related]
28. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care.
Gordin A; Golz A; Keidar Z; Daitzchman M; Bar-Shalom R; Israel O
Otolaryngol Head Neck Surg; 2007 Jul; 137(1):130-7. PubMed ID: 17599580
[TBL] [Abstract][Full Text] [Related]
29. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.
Brix G; Lechel U; Glatting G; Ziegler SI; Münzing W; Müller SP; Beyer T
J Nucl Med; 2005 Apr; 46(4):608-13. PubMed ID: 15809483
[TBL] [Abstract][Full Text] [Related]
30. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
Chen Z; Li X; Li F; Ouyang Q; Yu T
Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
[TBL] [Abstract][Full Text] [Related]
31. Role of functional imaging in the management of lymphoma.
Cheson BD
J Clin Oncol; 2011 May; 29(14):1844-54. PubMed ID: 21482982
[TBL] [Abstract][Full Text] [Related]
32. MRI and PET in monitoring response in lymphoma.
Rahmouni A; Luciani A; Itti E
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S106-12. PubMed ID: 16361125
[TBL] [Abstract][Full Text] [Related]
33. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria).
Rahmouni A; Luciani A; Itti E
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S102-6. PubMed ID: 16361124
[TBL] [Abstract][Full Text] [Related]
34. Sciatic nerve neurolymphomatosis - extent and therapy response assessment with PET/CT.
Strobel K; Fischer K; Hany TF; Poryazova R; Jung HH
Clin Nucl Med; 2007 Aug; 32(8):646-8. PubMed ID: 17667443
[TBL] [Abstract][Full Text] [Related]
35. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
36. FDG PET/CT flip flop phenomenon in treated lymphoma of bone.
Lin EC
Clin Nucl Med; 2006 Dec; 31(12):803-5. PubMed ID: 17117078
[TBL] [Abstract][Full Text] [Related]
37. Screening for cancer with PET and PET/CT: potential and limitations.
Schöder H; Gönen M
J Nucl Med; 2007 Jan; 48 Suppl 1():4S-18S. PubMed ID: 17204716
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of the predictive value of mid-treatment 18F-FDG-PET/CT scans in pediatric lymphomas and undefined criteria of abnormality in quantitative analysis.
Zhu HJ; Halkar R; Alavi A; Goris ML
Hell J Nucl Med; 2013; 16(3):169-74. PubMed ID: 24137579
[TBL] [Abstract][Full Text] [Related]
39. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
40. Magnetic resonance imaging of malignant lymphoma.
Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
